SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Full Disclosure Trading
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sultan who wrote (7651)2/3/2004 2:45:27 PM
From: Ian@SI  Read Replies (2) of 13403
 
OT

I also took a token position in my previously owned and sold QLTI on Friday.. Their potential competitor is EYET, which went public couple of days ago (in PH III trial) so only QLTI in their niche..

Given that this is a daytrading thread, your swap may well be a winning one. But Macugen (EYET's PhIII product) requires an injection directly into the eyeball 6 times a year. The risk of serious side effects is much higher than that for Visudyne which requires only 3 annual injections into the arm and effectiveness relative to placebo doesn't seem to be nearly as good for Macugen. Unless they come up with different facts as they complete their PHIII, I can guarantee that there's at least one potential patient (me) who will take Visudyne treatment rather than Macugen.

FWIW,
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News